Rebecca Jane Cox Brokstad

Professor, Head of the Influenza Centre

Department of Clinical Science

Influenza Centre

E-mailRebecca.Cox@uib.no
Phone+47 55 97 46 68+47 452 42 974
Visitor Address
5th Floor Laboratory Building

Jonas Leis vei 87

5021 Bergen

Room
Office address: Room 114 Armauer Hansens Hus
Postal Address
Postboks 7804

5020 Bergen

Publications

Academic article

Show author(s) (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 18 pages.
Show author(s) (2023). VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe. Vaccine. 3915-3922.
Show author(s) (2023). SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. Frontiers in Immunology.
Show author(s) (2023). Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. Frontiers in Public Health. 13 pages.
Show author(s) (2023). Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice. Frontiers in Immunology.
Show author(s) (2023). Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. EBioMedicine. 10 pages.
Show author(s) (2023). Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity. 1927-1938.e8.
Show author(s) (2023). Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study. Frontiers in Immunology.
Show author(s) (2023). Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews.
Show author(s) (2023). Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit. JMIR Public Health and Surveillance.
Show author(s) (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine: X. 1-11.
Show author(s) (2023). Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time. Nature Communications.
Show author(s) (2023). An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study. Frontiers in Immunology.

Show author(s) (2022). Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study. Frontiers in Immunology. 17 pages.
Show author(s) (2022). Vaccination rates in Europe are not associated with online media intensity. JCOM - Journal of Science Communication. 15 pages.
Show author(s) (2022). VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. Vaccine. 4090-4097.
Show author(s) (2022). Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. npj Vaccines. 11 pages.
Show author(s) (2022). The performances of three commercially available assays for the detection of SARS‐CoV‐2 antibodies at different time points following SARS‐CoV‐2 infection. Viruses. 1-11.
Show author(s) (2022). The evolution of humoral immune responses to past and novel influenza virus strains gives evidence for antigenic seniority. Frontiers in Immunology. 1-15.
Show author(s) (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clinical Infectious Diseases.
Show author(s) (2022). Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses. npj Vaccines. 10 pages.
Show author(s) (2022). SARS CoV-2 Infection among Health Care Workers from Different Health Care Facilities in Western Norway: A Prospective, Cross-Sectional Study. Viruses. 8 pages.
Show author(s) (2022). Human organotypic airway and lung organoid cells of bronchiolar and alveolar differentiation are permissive to infection by influenza and SARS-CoV-2 respiratory virus. Frontiers in Cellular and Infection Microbiology. 1-23.
Show author(s) (2022). Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4<sup>+</sup> T cell immunity within the FLUCOP consortium. Frontiers in Immunology. 14 pages.
Show author(s) (2022). Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium. Frontiers in Immunology. 14 pages.
Show author(s) (2022). Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews. 13 pages.
Show author(s) (2022). Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLOS ONE. 16 pages.
Show author(s) (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine. 11 pages.
Show author(s) (2022). A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. International Journal of Molecular Sciences.

Show author(s) (2021). Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review. Frontiers in Immunology. 16 pages.
Show author(s) (2021). Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers. Frontiers in Immunology. 1-11.
Show author(s) (2021). Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response. npj Vaccines. 1-6.
Show author(s) (2021). Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection. Frontiers in Immunology. 1-13.
Show author(s) (2021). Lower antibiotic prescription rates in hospitalized COVID-19 patients than influenza patients, a prospective study. Infectious Diseases. 1-12.
Show author(s) (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 1607-1613.
Show author(s) (2021). Learning from the COVID-19 pandemic among migrants: An innovative, system-level, interdisciplinary approach is needed to improve public health . Scandinavian Journal of Public Health. 804-808.
Show author(s) (2021). Humoral and cellular immune responses in critically ill influenza A/H1N1-infected patients. Scandinavian Journal of Immunology. 1-9.
Show author(s) (2021). Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014). Frontiers in Immunology.
Show author(s) (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. The Lancet Regional Health - Europe. 9 pages.
Show author(s) (2021). Assay harmonization and use of biological standards to improve the reproducibility of the hemagglutination inhibition assay: A FLUCOP collaborative study. mSphere. 1-18.

Show author(s) (2020). Viral antigens elicit augmented immune responses in primary Sjögren's syndrome. Rheumatology. 1651-1661.
Show author(s) (2020). Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report. Biologicals (Print). 41-52.
Show author(s) (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. Journal of Infectious Diseases.
Show author(s) (2020). Responsiveness to influenza vaccination correlates with nkg2c-expression on nk cells. Vaccines. 1-18.
Show author(s) (2020). Point-of-care influenza testing impacts clinical decision, patient flow and length of stay in hospitalized adults. Journal of Infectious Diseases. 97-108.
Show author(s) (2020). Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. Journal of Infectious Diseases. 21-32.
Show author(s) (2020). Human antibodies targeting influenza B virus neuraminidase active site are broadly protective. Immunity. 852-863.
Show author(s) (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. Journal of Infectious Diseases. 1528-1537.

Show author(s) (2019). Vitamin D Deficiency is Associated with Increased Use of Antimicrobials among Preschool Girls in Ethiopia. Nutrients. 1-14.
Show author(s) (2019). No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination. Vaccine: X. 1-8.
Show author(s) (2019). Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines. Influenza and Other Respiratory Viruses. 1-7.
Show author(s) (2019). Low temperature and low UV indexes correlated with peaks of influenza virus activity in Northern Europe during 2010-2018. Viruses. 1-10.
Show author(s) (2019). Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination. Scandinavian Journal of Immunology. 1-12.
Show author(s) (2019). Common nodes of virus-host interaction revealed through an integrated network analysis. Frontiers in Immunology. 12 pages.

Show author(s) (2018). T follicular-like helper cells in the peripheral blood of patients with primary Sjögren's syndrome. Scandinavian Journal of Immunology. 1-15.
Show author(s) (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research. 174-182.
Show author(s) (2018). Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine. Vaccine. 2213-2219.
Show author(s) (2018). Impact of erythrocyte species on assays for influenza serology. Journal of Preventive Medicine and Hygiene (JPMH). E1-E7.
Show author(s) (2018). Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines. 10 pages.
Show author(s) (2018). Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: A 5-year follow-up study. Clinical Infectious Diseases. 382-392.
Show author(s) (2018). Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. European Journal of Neurology. 527-534.
Show author(s) (2018). Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness. Influenza and Other Respiratory Viruses. 191-200.

Show author(s) (2017). Mucosal administration of cycle-di-nucleotide-adjuvanted virosomes efficiently induces protection against influenza H5N1 in mice. Frontiers in Immunology. 1-15.
Show author(s) (2017). Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model. mBio. 1-13.
Show author(s) (2017). Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. Vaccine. 5666-5673.
Show author(s) (2017). High prevalence of humoral and cellular immunity to influenza viruses in preschool children living in Addis Ababa, Ethiopia. Open Forum Infectious Diseases. 6 pages.
Show author(s) (2017). Distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy. PLOS ONE. 14 pages.
Show author(s) (2017). Boosting of cross-reactive and protection-associated T cells in children after live attenuated influenza vaccination. Journal of Infectious Diseases. 1527-1535.
Show author(s) (2017). A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza. Journal of Virology. 1-13.

Show author(s) (2016). Self-reported influenza vaccination and protective serum antibody titers in a cohort of COPD patients. Respiratory Medicine. 53-59.
Show author(s) (2016). Salivary IgA from the sublingual compartment as a novel noninvasive proxy for intestinal immune induction. Mucosal Immunology. 884-893.
Show author(s) (2016). Pulmonary changes in Norwegian fatal cases of pandemic influenza H1N1 (2009) infection: a morphologic and molecular genetic study. Influenza and Other Respiratory Viruses. 525-531.
Show author(s) (2016). Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. Journal of Infectious Diseases. 740-749.
Show author(s) (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. Journal of Infectious Diseases. 722-731.
Show author(s) (2016). Interpandemic (Seasonal) influenza. ERS Monograph. 35-64.
Show author(s) (2016). Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies. Vaccine. 3576-3583.
Show author(s) (2016). Epitope specific T-cell responses against influenza A in a healthy population. Immunology. 165-177.
Show author(s) (2016). Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination. npj Vaccines.
Show author(s) (2016). Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. Vaccine. 191-198.

Show author(s) (2015). Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses. Journal of Immunological Methods (JIM). 95-101.
Show author(s) (2015). Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio. 13 pages.
Show author(s) (2015). The expression of B & T cell activation markers in children’s tonsils following live attenuated influenza vaccine. Human Vaccines & Immunotherapeutics. 1663-1672.
Show author(s) (2015). Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Human Vaccines & Immunotherapeutics. 1654-1662.
Show author(s) (2015). Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine. 4146-4154.
Show author(s) (2015). Need for more targeted measures - Only less severe hospital-associated infections declined after introduction of an infection control program. Journal of Infection and Public Health. 282-290.
Show author(s) (2015). Mortality related to hospital-associated infections in a tertiary hospital; repeated cross-sectional studies between 2004-2011. Antimicrobial Resistance and Infection Control. 1-8.
Show author(s) (2015). Matrix M H5N1 vaccine induces cross-H5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in ferrets. PLOS ONE.
Show author(s) (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. Journal of Infectious Diseases. 1541-1549.
Show author(s) (2015). Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge. Human Vaccines & Immunotherapeutics. 1235-1243.
Show author(s) (2015). Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines. 373-389.
Show author(s) (2015). Induction of local secretory IgA and multifunctional CD4+ T-helper cells following intranasal immunization with a H5N1 whole inactivated influenza virus vaccine in BALB/c mice. Scandinavian Journal of Immunology. 305-317.
Show author(s) (2015). Immune responses in acute and convalescent patients with mild, moderate and severe disease during the 2009 influenza pandemic in Norway. PLOS ONE. 16 pages.

Show author(s) (2014). The Influence of Tonsillectomy on Total Serum Antibody Levels. Scandinavian Journal of Immunology. 377-379.
Show author(s) (2014). Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 4550-4557.
Show author(s) (2014). Matrix M™ adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man. Human Vaccines & Immunotherapeutics. 2408-2416.
Show author(s) (2014). Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLOS ONE.
Show author(s) (2014). Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Journal of Virology. 13260-13268.
Show author(s) (2014). Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
Show author(s) (2014). Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward. BMC Infectious Diseases. 9 pages.
Show author(s) (2014). Divergent H7 immunogens offer protection from H7N9 virus challenge. Journal of Virology. 3976-3985.
Show author(s) (2014). An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clinical and Vaccine Immunology. 1153-1163.

Show author(s) (2013). A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza and Other Respiratory Viruses. 1181-1193.

Show author(s) (2012). The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza and Other Respiratory Viruses. 90-100.
Show author(s) (2012). The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Human Vaccines & Immunotherapeutics. 653-661.
Show author(s) (2012). T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. Journal of Infectious Diseases. 158-166.
Show author(s) (2012). Influenza-like illness in general practice in Norway: clinical course and attitudes towards vaccination and preventive measures during the 2009 pandemic. Family Practice. 139-146.
Show author(s) (2012). A(H1N1)pdm09 Vaccination of Health Care Workers: Improved Immune Responses in Low Responders Following Revaccination. Journal of Infectious Diseases. 1660-1669.

Show author(s) (2011). Pandemic influenza vaccination of hypogammaglobulinemic patients induces normal or elevated influenza-specific CD4+Th1-cell responses. Influenza and Other Respiratory Viruses. 376-379.
Show author(s) (2011). Pandemic Influenza Vaccination Elicits Influenza-Specific CD4(+) Th1-cell Responses in Hypogammaglobulinaemic Patients: Four case reports. Scandinavian Journal of Immunology. 210-218.
Show author(s) (2011). Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza and Other Respiratory Viruses. 426-437.
Show author(s) (2011). Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4(+) cells and strong mucosal and systemic antibody responses in mice. Vaccine. 4973-4982.
Show author(s) (2011). Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLOS ONE. 12 pages.
Show author(s) (2011). Evaluation of a virosomal H5N1 vaccine formulated with Matrix M (TM) adjuvant in a phase I clinical trial. Vaccine. 8049-8059.

Show author(s) (2010). An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 266-273.

Show author(s) (2009). Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine. 7367-7376.
Show author(s) (2009). A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice. Influenza and Other Respiratory Viruses. 21-28.
Show author(s) (2009). A phase I clinical trial of a PER.C6 cell grown inﬂuenza H7 virus vaccine. Vaccine. 1889-1897.
Show author(s) (2009). A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza and Other Respiratory Viruses. 107-117.

Show author(s) (2007). Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clinical and Laboratory Immunology. 978-983.
Show author(s) (2007). A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice. Scandinavian Journal of Immunology. 14-21.

Show author(s) (2006). The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 6585-6587.
Show author(s) (2006). The humoral and cellular responses induced locally and systematically after parenteral influenza vaccination in man. Vaccine. 6577-6580.
Show author(s) (2006). Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scandinavian Journal of Immunology. 467-475.

Show author(s) (2005). Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scandinavian Journal of Immunology. 36-44.
Show author(s) (2005). Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scandinavian Journal of Immunology. 342-352.

Show author(s) (2002). Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. Journal of Infectious Diseases. 878-884.
Show author(s) (2002). Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 14-23.

Show author(s) (2001). The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 4743-4749.
Show author(s) (2001). Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 14-23.
Show author(s) (2001). High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scandinavian Journal of Immunology. 243-247.

Academic lecture

Show author(s) (2023). Post COVID-19 condition in children and adolescents after delta infection and omicron reinfection.
Show author(s) (2023). Local Immunity After Influenza Vaccination.
Show author(s) (2023). Indo-European Consortium for Next Generation Influenza Vaccine Innovation.

Show author(s) (2022). SARS CoV-2 vaccines, what have we learnt and what is the future .
Show author(s) (2022). Covid-19 vaccine evaluation.

Show author(s) (2021). Pre-existing immunity and correlates of protection for Influenza.
Show author(s) (2021). Influenza and SARS-CoV-2 vaccines and the young immune system: should we vaccinate children.
Show author(s) (2021). Covid-19 i Bergen.

Show author(s) (2020). Influensa.
Show author(s) (2020). Case study: Influenza; impact of pre-existing immunity on study end points .
Show author(s) (2020). COVID-19 in the community and health care system in Bergen, Norway.
Show author(s) (2020). COVID-19 in the community and health care system in Bergen .

Show author(s) (2019). Immune responses to influenza A/H1N1pdm09 virus after adjuvanted pandemic and seasonal influenza vaccination in healthcare workers.
Show author(s) (2019). Critical Nodes of Viral Modulation Revealed Through an Integrated Network Analysis of Host-Virus Interaction Landscape.

Show author(s) (2018). Using human influenza vaccine studies to define next generation vaccines .
Show author(s) (2018). Subject selection and screening for susceptibility to challenge.
Show author(s) (2018). Should we vaccinate health care workers against influenza annually?
Show author(s) (2018). Should we annually vaccinate health care workers against influenza?
Show author(s) (2018). Hvorfor trenger vi fremdeles vaksiner? og Influensa en evig kamp. .

Show author(s) (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.

Show author(s) (2014). The Norwegian Influenza cohort study (NorFlu): immune responses in H1N1 pdm exposed versus non-exposed pregnant women.
Show author(s) (2014). The Norwegian Influenza cohort (NorFlu): immune responses in pdmH1N1 exposed versus non-exposed pregnant women.
Show author(s) (2014). Perinatal outcomes and children’s health after prenatal exposure to influenza infection and vaccination.

Show author(s) (2005). The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man.

Show author(s) (2004). The antibody response to parenteral influenza vaccination � A review of specificity, magnitude, rapidity and shortcomings.

Show author(s) (2003). The local and systemic immune response to parenterally administered inactivated influenza vaccine.
Show author(s) (2003). The local and systemic immune response to parenterally administered inactivated influenza vaccine.

Show author(s) (2002). Influenzaantigenspecific cells in human nasal mucosa.
Show author(s) (2002). Influenza-specific antibody producing cells in human nasal mucosa.
Show author(s) (2002). Influenza-specific antibody producing cells in human nasal mucosa.
Show author(s) (2002). Influenza specific antibodysecreting cells in nasal mucosa, prior to and after vaccination.
Show author(s) (2002). Influenza specific antibody secreting cells in nasal mucosa.

Show author(s) (2001). The level of influenzaspecific antibodysecreting cells in nasal mucosa, prior to an after vaccination.
Show author(s) (2001). The effect of relenza treatment on the early immune response induced after influenza vaccination.
Show author(s) (2001). The basal level of influenza specific antibody secreting cells in healthy subjects.
Show author(s) (2001). Influenza specific antibody secreting cells (I-ASC)in human nasal mucosa. Relation to tonsil, blood and parenteral vaccination.
Show author(s) (2001). Influensaantigenspecifika, antikroppsproducerande lymfocyter i human nasal slemhinne.
Show author(s) (2001). DNA vaccination with HA or NP encoding plasmids results in rapid viral clearance after viral challenge.
Show author(s) (2001). Antibodies from lymphocytes used as diagnostic markers: A novel approach.

Research groups

Inflammation

Research group for Infection and Microbiology